ArticleOrphanet journal of rare diseases2019
Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: a multicenter retrospective study.
Article in Orphanet journal of rare diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Assessing the effectiveness of etoposide treatment in adult haemophagocytic lymphohistiocytosis: a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).Annals of the rheumatic diseases · 2023Pooled it
- The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).Arthritis & rheumatology (Hoboken, N.J.) · 2023Pooled it
- Early management of hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a systematic literature review.EULAR rheumatology open · 2026Review
- [Clinical analysis of nine cases of hemophagocytic lymphohistiocytosis during pregnancy: characteristics, therapeutic strategies, and maternal-infant outcomes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- A Novel Engineering Cell Therapy Platform Mimicking the Immune Thrombocytopenia-Derived Platelets to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A Case Report of Pregnancy Complicated with Primary Hemophagocytic Lymphohistiocytosis.International journal of women's health · 2024Article
- The role of etoposide in the treatment of adult patients with hemophagocytic lymphohistiocytosis.Experimental hematology & oncology · 2023Article
- Haemophagocytic lymphohistiocytosis in pregnancy and the postpartum period: A retrospective case series analysis.NIHR open research · 2023Article
- Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.Cancers · 2022Review
- Haemophagocytic lymphohistiocytosis in pregnancy.Obstetric medicine · 2022Review
- Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.The journal of obstetrics and gynaecology research · 2022Review
- Case report and literature review: Hemophagocytic lymphohistiocytosis in a pregnant woman with systemic lupus erythematosus withFrontiers in oncology · 2022Article
- Chronic active Epstein-Barr virus-associated secondary hemophagocytic lymphohistiocytosis in pregnancy: a case report.BMC pregnancy and childbirth · 2021Article
- Haemophagocytic lymphohistiocytosis in pregnancy: a pertinent case during the COVID-19 pandemic.BMJ case reports · 2021Article
- Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis.Annals of hematology · 2021Article
- Hemophagocytic lymphohistiocytosis during pregnancy: a review of the literature in epidemiology, pathogenesis, diagnosis and treatment.Orphanet journal of rare diseases · 2021Review
- Pharmacological Activities of Aminophenoxazinones.Molecules (Basel, Switzerland) · 2021Review
- Adult-Onset Still's Disease Presenting as Macrophage-Activation Syndrome With Critical Illness in the Third Trimester of Pregnancy: A Case Report.Critical care explorations · 2021Article
- Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.American journal of obstetrics & gynecology MFM · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundHemophagocytic lymphohistiocytosis (HLH) is a rare severe clinical syndrome. HLH manifesting during pregnancy has been paid much attention in recent years. Despite the specificity of pregnancy-related HLH, there has not been any consensus regarding its treatment. According to a previous study, corticosteroid/IVIG is the mainstream therapy; however, the efficacy is controversial. Etoposide is an important agent in the HLH-94 regimen; nevertheless, its use is limited because of possible toxicity to the fetus.
methodsIn this study, we summarized 13 cases from 4 medical institutions from April 2011 to April 2018. Treatment regimens and outcomes were observed.
resultsThe median age was 26 (20-36) years old. The median gestational age was 28 (10-35) weeks. In these 13 patients, 10 were treated with methylprednisolone/IVIG and was effective in only two patients. In 6 patients who used etoposide during their treatment, all achieved remission. The median time from onset of disease to use of etoposide was 36 (17-131) days. Five of these 6 patients were treated with corticosteroids with/without IVIG before etoposide. One patient with pulmonary tuberculosis and one with lymphoma were treated according to etiology and achieved long survival.
conclusionFor treatment of pregnancy-related HLH, particularly for patients who do not respond to corticosteroids/IVIG therapy, etoposide should be used bravely. Nevertheless, suitable dosages and toxic and side-effects require further clinical observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.